|
Patent landscape, scope, and claims: |
United States RE50455 Patent Landscape: What Claims Cover, How Broad They Are, and Where Generic Risk Concentrates
RE50455 is a reissue-type U.S. patent whose claim 1 is built around a large “Formula (I)” chemical genus defined by a pyrazolopyridine-linked scaffold and extensive substituent permutations. Dependent claims then narrow to particular structural selections (notably Y as a carbonyl) plus specific compound sub-classes and, at the tail end, a specific salt form: the hemicalcium salt hydrate of a further-defined compound. The overall estate is structured as a genus-first claim set with multiple downstream embodiments and use/composition claims for Type 2 diabetes and obesity.
What is U.S. Patent RE50455 and what do the claims actually cover?
Claim structure summary
- Claim 1: a compound represented by Formula (I) with broad genus coverage (X, Y, Q1, Q2, R groups, R9/Z1/Z2 variability, plus salt option).
- Claims 2–10: narrower genus subsets (Q1 selection; R7/R8 and Z2 substitution patterns; Y fixed to —C(═O)—; R1 fixed to H; n1=n2=0; R9 fixed to a specific internal formula; X restricted to a set including —N═, —CH═, —CF═; then a specific Z1 formula).
- Claims 11–12: pharmaceutical composition and method-of-use claims for Type 2 diabetes/obesity.
- Claims 13–17: additional specific embodiments (multiple formula levels) culminating in hemicalcium salt hydrate.
- Claims 18–41: additional embodiment and use/composition coverage for the same defined compounds across different formula claim levels.
High-level takeaway
- Practically, RE50455 functions as a chemistry genus patent plus downstream embodiment patents tied to specific substitution patterns and at least one specific salt hydrate. The “risk surface” for a challenger is highest where a competitor’s structure still fits the Formula (I) variable definitions, particularly around Q1/Q2/Z2/R9/Z1 and the X and Y linkers.
How broad is claim 1 of RE50455 (Formula I), and where are the real claim boundaries?
Claim 1 boundary controls (the “safety-critical” variables)
Claim 1 is broad because it allows many groups to vary, but it is not limitless. The real boundaries are defined by these structurally meaningful slots:
1) Backbone linkers: X and Y
- X is limited to —N═ or —CRa═, with Ra = H, halogen, or C1–6 alkyl.
- Y is limited to —C(═O)—, —CHR—, or —S(═O)2—.
Why this matters
- These are front-door determinants of the core functional connectivity. Small changes (e.g., converting Y from amide-like carbonyl to a bioisostere not within the listed options) would fall outside claim 1.
2) Aromatic and heteroaryl regions: Q1 and Q2
- Q1: C6–10 aryl or 5–10 membered heteroaryl with 1–5 substituents from a defined set (halogen, C1–6 alkyl, C1–6 alkoxy, where alkyl may be halogen-substituted).
- Example narrowing later: claim 2 fixes Q1 to phenyl or pyridyl with 1–4 substituents from the same general set.
- Q2: 3–12 membered heterocyclyl or 5–10 membered heteroaryl with 0–3 substituents from a defined set including a nitrogen substituent pattern —NRQaRQb plus ring-fused carbocycle formation possibility (two alkyl groups plus carbon form C3–8 carbocyclic ring).
- Q2 substituents can include alkylcarbonyl and protected heterocycle variants limited to 3–12 members.
Why this matters
- These slots govern the lipophilicity and electronics; they are also the dominant degrees of freedom in patentable scope for kinase-like or receptor-like binding series.
3) Core substituents on the scaffold: R1–R8, R7/R8 ring option
- R1, R2, R3: H or C1–6 alkyl, where alkyl can carry halogen/alkoxy substitution.
- R4, R5, R6: H, halogen, or C1–6 alkyl.
- R7 and R8: H or C1–6 alkyl, with option for R7+R8 together with the attached carbon to form C3–15 cycloalkane ring.
- Cycloalkane substitution is limited with optional C1–6 alkyl (itself halogen-substituted etc.), plus hydroxy, —NR7aR7b, C1–6 alkoxy, or 3–12 membered heterocyclyl.
Why this matters
- This part is a common “genus within a genus” region: many distinct members will still fit, but a competitor that removes a ring option or introduces substituents not in the allowed list loses literal coverage.
4) “R9 slot” and linker region: n1, n2, R9, R9a–R9i, n3
- n1 = 0–3, n2 = 0–5, n3 = 0–2.
- R9 is selected from:
- —CO2R9f, and
- —C(═O)—NR9gR9h.
- The allowed values for R9f, R9g, R9h, and substituted alkyl groups are spelled out (H, C1–6 alkyl, alkylcarbonyl options; and R9h can include cyano and sulfone-like —S(═O)n3—R9i).
Why this matters
- This is where competitors often tweak solubility and PK. The claim’s enumerated carbonyl and carboxyl/sulfonamide-like boundaries create a clear exclusion zone for groups not conforming to the allowed R9 pattern.
5) Z1 and Z2: substituted binding-position chemistry
- Z1: selected from a group containing a further-defined sub-structure with Rza (H, C1–6 alkyl, or alkylcarbonyl), and Rzb/Rzc (H or alkyl).
- Z2: selected from alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, each with up to one to five substituents from a defined set, including:
- oxo,
- halogen,
- cyano,
- —NRzdRze (with Rzd/Rze = H, alkyl, alkylcarbonyl with optional alkoxy on alkyl),
- —C(═O)—NRzfRzg,
- —S(═O)n7—Rzh (n7 0–2),
- C1–6 alkyl (optionally substituted with halogen, hydroxy, —NRziRzj, alkoxy, or heterocycle),
- C1–6 alkoxy (optionally substituted with hydroxy/halogen/alkoxy),
- 3–12 membered heterocyclyl (optionally substituted with alkyl and alkylcarbonyl),
- C6–10 aryl substituted with up to alkylcarbonyl,
- 5–10 membered heteroaryl optionally substituted with alkyl, alkoxy, —NRzkRzl, and additional heterocycle substitutions.
Why this matters
- Z2 is a major scope driver. It is also where non-literal design-around strategies usually begin (different heteroaryl cores, different substitution counts, or substituent types not in the Group A list).
Which dependent claims narrow RE50455, and how do they affect freedom-to-operate?
Claim 2 (Q1 fixed to phenyl/pyridyl)
- Q1 is phenyl or pyridyl with 1–4 substituents from halogen and C1–6 alkyl.
- This is a narrowing step from claim 1.
Claim 3 (R7/R8 patterns and cycloalkane options)
- R7/R8 options:
- both H,
- both alkyl,
- mixed H/alkyl,
- or cycloalkane formation C3–8 (substituted with 1–2 C1–6 alkyl; where alkyl may be substituted with hydroxy, alkoxy, and 3–12 membered heterocyclyl).
Claim 4 (Z2 substitution menu restricted to Group B; max substituents reduced)
- Z2 substituents become capped and curated via Group B:
- oxo,
- halogen,
- —NRzd1Rze1 (with allowed R groups),
- —S(═O)n7—Rzh1,
- C1–6 alkyl (optionally substituted with halogen, hydroxy, —NRziRzj, alkoxy, and heterocycle),
- C1–6 alkoxy,
- heterocyclyl,
- 5–10 membered heteroaryl with allowed N-substitution (—NRzk1Rzl1) where R are H or alkyl.
Claim 5 (Y fixed)
Claim 6–7 (R1 fixed and n1/n2 fixed to zero)
- R1 is H.
- n1 = 0 and n2 = 0.
Claim 8 (R9 fixed to a specific formula)
- R9 is set to “Formula” (not text-readable here), which is a strong narrowing.
Claim 9 (X restricted further)
- X is limited to —N═, —CH═, or —CF═.
Claim 10 (Z1 fixed to a specific formula)
- Z1 is fixed to a particular Z1 substructure with binding-position definitions for “*” and “**”.
FTO implication
- If a competitor’s scaffold does not match the exact fixed options in claims 5–10, they still might fall within claim 1 if those specific narrowing predicates are not satisfied but the general claim 1 remains met. Conversely, if a competitor fits claim 1 but not the narrowing selections, claim 1 still blocks.
Does RE50455 claim pharmaceutical compositions and methods of use for Type 2 diabetes and obesity?
Yes.
Claim 11: pharmaceutical composition with the compound (or salt) as the active ingredient.
Claim 12: method treating Type 2 diabetes (non-insulin-dependent) or obesity by administering an effective amount.
Subsequent method claims repeat these indications with specific compound embodiments tied to claim 18/19/20/21/…:
- Claims 17, 24, 25, 26: method using the hemicalcium salt hydrate or the compound of claim 18 (as applicable in the chain).
- Claims 29–31: hyperglycemia and obesity/Type 2 diabetes treatment methods tied to claim 19.
- Claims 34–36: similar treatment methods tied to claim 20.
- Claims 39–41: similar treatment methods tied to claim 21.
Claim breadth
- The use claims are not limited to routes, dosing schedules, or patient subtypes in the text provided. That gives them a high functional coverage profile as long as the administered compound is inside the claim scope.
What do the salt and salt-hydrate claims cover, and why are they litigation-relevant?
Claim 15: the hemicalcium salt hydrate of the compound according to claim 14.
Claim 21: “a compound of” the hemicalcium salt hydrate compound of claim 14 (as written).
Claims 16–17: composition and method claims for the compound of claim 14 and the hemicalcium salt hydrate.
Why salt forms matter
- Even if a competitor uses a different salt or avoids hydrate, the genus claims may still reach the free base if the molecule otherwise matches Formula (I). But if the commercial lead is the hemicalcium salt hydrate, the specific downstream claims strengthen exclusivity and reduce design-around options based on salt selection.
How many claim “families” does RE50455 create in practice?
From the claim text provided, RE50455 effectively organizes coverage into at least four overlapping layers:
- Genus (Claim 1): formula-level compound coverage with defined enumerations for core variable positions.
- Genus subsets (Claims 2–10): fixed choices for Q1, Y, R1, n1/n2, R9, X, Z1, and Z2 substitution patterns.
- Embodiment cascades (Claims 13–21 and 18–21 blocks): additional formula claim levels including a specific hemicalcium salt hydrate.
- Product and use coverage (Claims 11–12, 16–17, 22–41): compositions and treatment methods tied to the covered embodiments.
Practical implication
- A challenger cannot target only one structural fragment. If their molecule is close but misses one narrowing predicate, claim 1 still may capture them unless the missed feature is a claim-1 boundary variable.
What generic entry risks exist for RE50455, given the claim format?
Risk concentrates in two places
- Literal scope of the Formula (I) genus (Claim 1). If the competitor’s active fits that genus, both free base and covered salts are blocked at the compound level.
- Salt-hydrate and composition claims: even if a generic tries to switch salt form, if it still uses a compound member within Claim 1 and a claimed embodiment chain, composition and method claims remain at risk.
Paragraph IV strategic reality
- For a Paragraph IV, the generic applicant typically argues non-infringement (structure/design-around) and/or invalidity.
- The claim’s enumerated variable lists make structural non-infringement plausible if the design-around changes one of the “slot categories” outside the enumerated sets (X, Y, R9 pattern, Z1/Z2 core definitions).
Where design-arounds are harder
- When the claims fix multiple high-impact positions simultaneously (Y=carbonyl; n1=n2=0; X among N═/CH═/CF═; Z1 fixed), a generic would need a coordinated redesign rather than a single-point tweak.
What is the key “claim-engine” for deciding infringement quickly?
The fastest infringement screen against RE50455 is to map a candidate molecule to these claim 1 slot categories:
- Does it have X equal to one of: —N═ or —CRa═ with Ra in {H, halogen, C1–6 alkyl}?
- Does it have Y in {—C(═O)—, —CHR—, —S(═O)2—}?
- Does it contain Q1 within C6–10 aryl or 5–10 membered heteroaryl with substitutions limited to halogen, C1–6 alkyl, C1–6 alkoxy (with halogen-substituted alkyl allowed)?
- Does Q2 fall within 3–12 membered heterocyclyl or 5–10 membered heteroaryl with substituent count limited and substituents limited to the enumerated list?
- Does R9 conform to the two permitted carbonyl/carboxyl motifs and the enumerated substituent space (including sulfone-like option with constraints)?
- Does the molecule’s Z1 and Z2 definitions match the allowed families and substituent groups?
If all six map, claim 1 is a direct block. If one slot fails, downstream claims may still capture the compound unless the failure aligns with a claim 1 boundary.
How does RE50455 compare with typical U.S. small-molecule genus patents in scope and litigation posture?
Compared with common genus patents
- RE50455 is closer to a “high-permutation genus with enumerated chemistry” than a fully open functional-genus claim.
- The presence of a fixed salt hydrate claim suggests the applicant did not rely solely on abstract genus coverage. That usually increases litigation leverage when the marketed product’s API is sold as that salt form.
Litigation posture implication
- Infringement fights are likely to pivot on:
- whether a competitor’s substituted heteroaryl core matches Q1/Q2/Z2 limits,
- whether Y and X match the allowed linker classes, and
- whether R9 pattern and Z1 constraints are satisfied.
Key Takeaways
- Claim 1 of RE50455 is a broad but enumerated Formula (I) genus built on a specific scaffold architecture using controlled variable lists for X, Y, Q1, Q2, R9, Z1, and Z2.
- Dependent claims 2–10 tighten scope by fixing key structural slots (notably Q1, Y=—C(═O)—, R1=H, n1=n2=0, X among —N═/—CH═/—CF═, and fixed Z1 plus Z2 substitution constraints).
- Composition and method-of-use claims cover pharmaceutical compositions and treatment of Type 2 diabetes and obesity (and related hyperglycemia) when administered compound embodiments fall within the claim chain.
- Salt focus: the estate includes a specific hemicalcium salt hydrate embodiment, strengthening product-form exclusivity alongside the free-base/molecular genus risk.
FAQs
1) What structural elements matter most for infringement of RE50455?
X and Y (allowed linker classes), plus mapping of Q1/Q2/Z2 to their enumerated aromatic/heteroaryl and substituent sets, and alignment of R9 with its limited carbonyl/carboxyl/sulfone-linked motifs.
2) If a competitor changes the salt form, does RE50455 still block them?
Claim 1 covers compounds “and/or salts thereof,” so a different salt does not automatically avoid infringement if the active molecule still fits Formula (I). Salt-hydrate claims add additional coverage tied to the hemicalcium salt hydrate embodiment.
3) Does RE50455 protect only Type 2 diabetes, or also obesity?
Both are covered in the method claims: Type 2 diabetes and obesity are explicitly listed.
4) Where are design-around strategies most likely to succeed?
Where the candidate molecule breaks at least one claim-1 boundary variable category, especially the enumerated sets for X, Y, R9, or the Z1/Z2 defined aromatic/heteroaryl and substitution-group constraints.
5) Are the dependent claims more important than claim 1 for freedom-to-operate?
Claim 1 is most important because it is the broadest compound-level gate. Dependent claims are still relevant because they define specific subsets and anchored embodiments, including the hemicalcium salt hydrate, tied to compositions and methods.
References (APA)
No sources were provided for RE50455’s bibliographic data, prosecution history, or confirmatory claim text from official USPTO or FDA Orange Book records beyond the claim text included in the prompt.
More… ↓
⤷ Start Trial
|
